Brought to you by 
Astellas licenses Asian rights to XenoPort's XP13512
18 Jan 2012
Executive Summary
In its first drug development collaboration, XenoPort (improves existing therapeutics) licensed Japanese company Astellas Pharma (Yamanouchi/Fujisawa merger) exclusive rights to develop and commercialize its gabapentin prodrug XP13512 in Japan, Korea, the Philippines, Indonesia, Thailand, and Taiwan.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astellas licenses Asian rights to XenoPort's XP13512
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice